Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2419Neoplasms 1838Carcinoma, Non-Small-Cell Lung 1591Prostatic Neoplasms 1296Colorectal Neoplasms 1117Lung Neoplasms 981Neoplasm Metastasis 828Multiple Myeloma 793Leukemia, Myeloid, Acute 773Ovarian Neoplasms 673Pancreatic Neoplasms 667Melanoma 660Squamous Cell Carcinoma of Head and Neck 589Recurrence 563Carcinoma, Hepatocellular 562Brain Neoplasms 515Glioblastoma 505Stomach Neoplasms 501Head and Neck Neoplasms 492Triple Negative Breast Neoplasms 471Lymphoma 460Uterine Cervical Neoplasms 444Carcinoma, Renal Cell 426Precursor Cell Lymphoblastic Leukemia-Lymphoma 420Lymphoma, Non-Hodgkin 387Endometrial Neoplasms 377Sarcoma 365Lymphoma, Follicular 357Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

testosterone enanthate 1testosterone 17 beta-cypionate 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castration Resistant Metastatic Prostate Cancer × 1 year × Clear all
NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
150 enrolled
Genitourinary

Castration Resistant Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡